Evidence map›Paper›PMID 35287643›Full record

ReviewBMC endocrine disorders2022

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.

Sjaak Pouwels, Nasser Sakran, Yitka Graham, Angela Leal, Tadeja Pintar, Wah Yang, Radwan Kassir, Rishi Singhal, Kamal Mahawar, Dharmanand Ramnarain

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05733897 (Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis), which is not on this map. Cited by 480 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 6 pooled it
117.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05733897 unknown statusnot on this map

Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis

TypeobservationalSponsorNational Taiwan University HospitalRan2022 to 2025Enrolled150ConditionsNonalcoholic SteatohepatitisArmshydroxychloroquine
3 · Its place in the literature

Who cites it

480 citing papers in PubMed, 6 syntheses or guidelines pooled it, 809 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Food science & nutrition · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

420 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Sjaak PouwelsDepartment of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, Hilvarenbeekseweg 60, P.O. Box 90151, 5000 LC, Tilburg, The Netherlands. sjaakpwls@gmail.com.ORCID http://orcid.org/0000-0002-6390-7692
Nasser SakranDepartment of Surgery, Holy Family Hospital, Nazareth, Israel, and the Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Yitka GrahamFaculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK.
Angela LealDepartment of Bariatric Surgery, Christus Muguerza Conchita Hospital, Monterrey, Mexico.
Tadeja PintarDepartment of Abdominal Surgery, University Medical Center Ljubljana, Zaloška cesta, Ljubljana, Slovenia.
Wah YangDepartment of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Radwan KassirCHU Félix Guyon, Allée des Topazes, Saint-Denis, France.
Rishi SinghalBariatric and Upper GI Unit, Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
Kamal MahawarFaculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK.
Dharmanand RamnarainDepartment of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, Hilvarenbeekseweg 60, P.O. Box 90151, 5000 LC, Tilburg, The Netherlands.
Elisabeth-TweeSteden Ziekenhuis · NLBar-Ilan University · ILFirst Affiliated Hospital of Jinan University · CNLjubljana University Medical Centre · SISouth Tyneside and Sunderland NHS Foundation Trust · GBUniversidad Anáhuac · MXUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public health. NAFLD is the most common chronic liver disease in the Western world. NAFLD is closely associated with metabolic disorders, including central obesity, dyslipidaemia, hypertension, hyperglycaemia and persistent abnormalities of liver function tests.In general NAFLD is a common denominer for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis. This is normally seen on liver biopsy and can range from milder forms (steatosis) to the more severe forms (non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis and liver failure). In these patients, advanced fibrosis is the major predictor of morbidity and liver-related mortality, and an accurate diagnosis of NASH and NAFLD is mandatory. Histologic evaluation with liver biopsy remains the gold standard to diagnose NAFLD. Diagnosis of NAFLD is defined as presence of hepatic steatosis, ballooning and lobular inflammation with or without fibrosis. Weight loss, dietary modification, and the treatment of underlying metabolic syndrome remain the mainstays of therapy once the diagnosis is established. Dietary recommendations and lifestyle interventions, weight loss, and the treatment of underlying metabolic syndrome remain the mainstays of therapy once the diagnosis is established with promising results but are difficult to maintain. Pioglitazone and vitamin E are recommended by guidelines in selected patients. This review gives an overview of NAFLD and its treatment options.

Indexed as

Diet TherapyNon-alcoholic Fatty Liver DiseaseWeight LossHumansHypoglycemic AgentsVitamin EHypoglycemic AgentsVitamin EBariatric surgeryConservative therapyMetabolic surgeryNAFLDNon-alcoholic fatty liver diseaseWeight management

Identifiers

PMID35287643
PMCPMC8919523
OpenAlexW4220832833

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.